Herbal TB Immunotherapy to be Presented at Hong Kong Conference
07 Julho 2011 - 11:33AM
Immune Network Ltd. (Pink Sheets:IMMFF) advises that clinical
results from its new tableted form of Immunoxel (Dzherelo) product
demonstrated improved efficacy and shortened duration of treatment
compared to the original liquid formulation. Ekomed is presenting
these latest findings, as well as further results with Immunitor's
V5 immunotherapy against TB, this week at the 3rd Asia Pacific
Region Conference of the International Union Against Tuberculosis
and Lung Disease held in Hong Kong on July 8-11, 2011.
Immunoxel has been demonstrated in a dozen published clinical
trials to have a powerful effect against active tuberculosis,
including the drug-resistant forms (MDR-TB and XDR-TB) and a
significant improvement in TB/HIV patients vs standard therapy
alone. The new tableted formulation has major advantages in terms
of lower cost of production and of distribution, and is expected to
exhibit much greater patient compliance due to simplified mode of
administration. Although Immunoxel acts as an immunomodulator, it
is currently sold as a herbal dietary supplement.
Immune Network recently signed a deal with Australian healthcare
company Stirling Products Limited (ASX:STI) to make Immunoxel
available and affordable for the patients who need such products.
The market potential for products such as Immunoxel and V5 is
large, since there are 9 million new cases of TB annually and 2
billion people are infected with the bacillus. Drug-resistant forms
of TB – MDR-TB and XDR-TB and TB/HIV – are global health
priorities.
The website for Immune Network is at
http://www.immune-network.com.
The Immune Network Ltd. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8008.
Safe Harbor Statement
The information in this release, other than historical
information, may be considered forward-looking statements within
the provisions of the Private Securities Litigation Reform Act of
1995. Projection and other forward-looking statements and
management expectations regarding future events and/or financial
performance of the Company -- although given in good faith -- are
inherently uncertain and actual events and/or results may differ
materially.
CONTACT: Immune Network Ltd.
IMMFF@yahoo.com
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024
Notícias em tempo-real sobre Omni Bridgeway Ltd (PK) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Immune Network Ltd